PT-CY With or Without Low-dose ATG for Lymphoid Malignancies Undergoing Allo-HSCT

GVHD, Acute Clinical Trial

Official title:
Post Transplantation Cyclophosphamide With or Without Low-dose ATG for Patients With Lymphoid Malignancies Undergoing Allogeneic Stem Cell Transplantation

Status Completed

Clinical Trial Summary

All patients received Flu-BU-VP16 as myeloablative conditioning followed by cyclophosphamide (D+3 and +4) and subsequent tacrolimus. For patients with unrelated or haplo-donor received low-dose ATG at Day +15.

Clinical Trial Description

For patients with high-risk lymphoid malignancies, patients will undergo allo-HSCT from HLA matched sibling, unrelated (9~10/10) donor or hallo-identical donors. For all patients will receive myeloablative conditioning with 5-day fludarabine, 2-day VP-16 and 3-day busulifan. For prophylaxis graft versus host disease (GVHD), patients will receive cyclophosphamide 50mg/kg daily on D+3 and +4 with subsequent tacrolimus starting at D+5. For patients receiving HSCT from unrelated or haplo-donor, low-dose ATG 2.5mg/kg will be given on Day +15. ;

Study Design

Related Conditions & MeSH terms

GVHD, Acute

Clinical Trial Details

NCT number	NCT04118075
Study type	Interventional
Source	Shanghai Jiao Tong University School of Medicine
Contact
Status	Completed
Phase	Phase 2
Start date	January 1, 2019
Completion date	May 1, 2021

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03763318` - A Study to Evaluate the Safety, Tolerability, PK, PD, and Clinical Activity of EQ001 in Subjects With aGVHD	Phase 1/Phase 2
Completed	`NCT03605927` - CD40-L Blockade for Prevention of Acute Graft-Versus-Host Disease	Phase 1
Recruiting	`NCT04118556` - Decidua Stroma Cells for Steroid Resistent Acute Graft-versus-host Disease After Allo-HSCT	Phase 1/Phase 2
Active, not recruiting	`NCT03371667` - To Compare the Efficacy of the Addition of Methotrexate (MTX) to Current Standard Acute Graft-versus-host Disease (GVHD) First-line Treatment With Corticosteroids	Phase 3